

BIOGRAPHICAL SKETCH

Name	Position Titles:		
Joseph Paladino	Director, Clinical Outcomes & Pharmacoeconomics CPL Associates LLC, Amherst, NY		
Institution	Degree	Year	Field of Study
Siena College, Loudonville, NY	B.S.	1975	Biology
Massachusetts College of Pharmacy	B.S.	1977	Pharmacy
Medical University of South Carolina	Pharm.D.	1982	Pharmacy

Research and Professional Experience:

2001-present	Director, Clinical Outcomes and Pharmacoeconomics CPL Associates LLC, Amherst, NY
1993-present	Clinical Associate Professor of Pharmacy, State University of New York at Buffalo
1990-2000	Director, Pharmacoeconomics, Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospitals, Buffalo NY
1990-1993	Clinical Assistant Professor of Pharmacy, SUNY at Buffalo
1989-present	Adjunct Assistant Professor of Nursing, SUNY at Buffalo
1987-2000	Director, Suburban Hospital Division, Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospitals, Buffalo NY
1986-1987	Clinical Pharmacologist in Medicine and Pediatrics, Adjunct Medical Staff Rochester General Hospital, Rochester, NY
1985-1987	Clinical Instructor in Pediatrics University of Rochester School of Medicine and Dentistry, Rochester, NY
1982-1987	Assistant Director of Pharmacy for Clinical and Educational Services Rochester General Hospital, Rochester, NY
1980-1982	Decentralized Pharmacist, Medical University Hospital, Charleston SC
1979-1980	Chief Pharmacist (Acting), Utica Psychiatric Center, Utica NY
1978-1980	Staff Clinical Pharmacist, Utica Psychiatric Center, Utica NY
1978-1980	Community Pharmacist (part-time), Whitesboro Pharmacy, Whitesboro NY

Professional Societies:

American College of Clinical Pharmacy (ACCP)

1995-present	Co-Editor, Outcomes & Economics Curriculum Course & College Course
1995-1996	Pharmacoeconomics Subcommittee Chair, Outcomes & Economics PRN
1994-1995	Founder and Chair, Outcomes & Economics PRN
1993-present	Abstract reviewer Research award reviewer
1993	Nominations Officer, New York State Chapter

The Society of Infectious Diseases Pharmacists (SIDP)

2001	10 year Compendium Committee
1993	Specialization Working Group

New York State Council of Hospital Pharmacists (NYSCHP)

1989	Chair, 17th Annual Midyear Clinical Meeting (MCM)
1988	Vice Chair, 16th Annual MCM
1987	Registration Chair, 15th Annual MCM
1986-1987	Elected delegate to Annual Meeting

American Society of Health-System Pharmacists (ASHP)

1987-1988	Program Planning, Clinical Pharmacokinetics SIG
1986-1987	Nominations Committee, Clinical Pharmacokinetics SIG
1984-1985	Program Planning, Clinical Pharmacokinetics SIG

New York Academy of Sciences

Infectious Diseases Society of America (IDSA)

American Society for Microbiology (ASM)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Medical Outcomes Trust

Awards and Honors

1998	Excellence in Research Award, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
1998	Who's Who in the World (editions 16, 17, 18, 19)
1996	Who's Who in Medicine and Healthcare (editions 1, 2, 3)
1996	Fellow, American College of Clinical Pharmacy
1995	Who's Who in the East (editions 26, 27, 28)
1994	Who's Who in Science and Engineering (editions 2, 3, 4, 5, 6)
1994	Who's Who in America (editions 48, 49, 50, 51, 52, 53, 54, 55, 56)
1992	Visiting Professor of Clinical Pharmacy, Tayside Health Board, Scotland
1982	Sandoz Award for Superior Academic Achievement
1980	Columbia University Alumni Association Scholarship Award
1976	Rho Chi Pharmaceutical Honor Society

Editorial Boards

2001–present	Consulting Editor, <i>PharmacoEconomics</i>
1999–present	Editorial Board, <i>Surgical Infections</i>
1995–present	Editorial Board, <i>Journal of Infectious Disease Pharmacotherapy</i>
1982–present	Reviewer: <i>Clinical Infectious Diseases; Pharmacotherapy; Drugs; PharmacoEconomics; Antimicrobial Agents and Chemotherapy; Journal of Antimicrobial Chemotherapy; Annals of Pharmacotherapy; Infections in Medicine; Journal of Pharmacy Technology; Drug Benefit Trends; American Journal of Health-Systems Pharmacy; The Cancer Journal</i>

Publications (Representative selection):

1. Paladino JA, Crass RE. Amphotericin B and flucytosine in the treatment of candidal cystitis. *Clin Pharm.* 1982;1:349-352.
2. Paladino JA, Blumer NA, Maddox RR. Effect of secobarbital on theophylline clearance. *Ther Drug Monit.* 1983;5:135-139.
3. Canaday BR, Poe TE, Sawyer WT, Paladino JA. Fractional adjustment of predicted creatinine clearance in females. *Am J Hosp Pharm.* 1984;41:1842-1843.
4. Anton RF, Paladino JA, Morton WA, Thomas RW. The effect of acute alcohol consumption on lithium kinetics. *Clin Pharmacol Ther.* 1985;38:52-55.
5. Paladino JA. Oral treatment of serious infections with ciprofloxacin, a new quinolone antibiotic. *Hosp Pharm.* 1988;23:134-138.
6. Paladino JA. Economic implications of oral fluoroquinolone therapy. In: Sanders WE, Sanders CC, eds. Fluoroquinolones in the Treatment of Infectious Disease. Glenview, IL: Physicians & Scientists Publishing Co., Inc.; 1990:249-262
7. Paladino JA, Sperry H, Backes JM, Gelber J, Jones DA, Cumbo TJ, Schentag JJ. Clinical and economic evaluation of oral ciprofloxacin following an abbreviated course of intravenous antibiotics. *Am J Med.* 1991;91:462-470.
8. Grasela TH, Paladino JA, Schentag JJ, Huepenbecker D, Rybacki J, Purcell J, Fiedler JB. The clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. *DICP, Ann Pharmacother.* 1991;25:857-862.
9. Paladino JA. Streamlining antibiotic therapy: clinical application of pharmacokinetic and pharmacodynamic principles. *J Osteopath Med.* 1991;5:16-25.
10. Schentag JJ, Ballow CM, Paladino JA, Nix DE. Dual individualization of antibiotics. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. Vancouver WA: Applied Therapeutics, Inc. Third Edition; 1992, 17:1-20.
11. Paladino JA. Relationship of clinical pharmacy and cost containment in antimicrobial therapies. *Eur J Hosp Pharm.* 1992;2:83-87.
12. Schentag JJ, Ballow CH, Fritz AL, Paladino JA, Williams JD, Cumbo TJ, Ali RV, Galletta VA, Gutfeld MB, Adelman MH. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. *Diagn Microbiol Infect Dis.* 1993;16:255-264.
13. Nix DE, Ballow CH, Forrest A, Paladino JA, Birmingham MC, Cumbo TJ, Schentag JJ. Dosing considerations with intravenous ciprofloxacin in critical care patients. In: Gemmell CG, ed. Ciprofloxacin in Hematology and Oncology. Raven Press, Ltd, New York, 1993:45-55.
14. Paladino JA. P.E.A.C.E. (PharmacoEconomic Antibiotic Cost Evaluator). Developed concept, wrote the software. Manual published, software distributed by BMS, 1993.
15. Paladino JA. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis. *PharmacoEconomics.* 1994;5:505-512.
16. Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. *Ann Pharmacother.* 1994;28:384-389.
17. Davey PG, Paladino JA. (Guest Editors) Pharmacoeconomics of oral antibiotics. *PharmacoEconomics.* 1994;5(Suppl 2):1-43.
18. Paladino JA. Pharmacoeconomic comparison of ciprofloxacin and ceftazidime. *Can J Hosp Pharm.* 1995;48:276-283.
19. Schentag JJ, Paladino JA, Birmingham MC, Zimmer G, Carr JR, Hanson SC. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. *J Pharm Technol.* 1995;11:203-210.
20. Paladino JA, Zimmer GS, Schentag JJ. The economic potential of dual individualization methodologies. *PharmacoEconomics.* 1996;6:539-545.
21. Rifenberg RP, Paladino JA, Hanson SC, Tuttle JA, Schentag JJ. Benchmark analysis of strategies hospitals use to control antimicrobial

- expenditures. *Am J Health-System Pharm.* 1996;53:2054-2062.
22. Paladino JA. Survey of ACCP members regarding economics, outcomes management, and outcomes research. *Pharmacotherapy.* 1996;16:267-270.
 23. Schentag JJ, Carr JR, Adelman MH, Birmingham MC, Zimmer G, Paladino JA. Formulary management vs disease management. *Infect Dis Clin Pract.* 1996;5(Suppl 1):1-6
 24. Paladino JA. Health outcomes and pharmacoeconomics: an ID pharmacist's perspective. *Infect Med.* 1996;13 (suppl B):43-49.
 25. Paladino JA. P.E.A.C.E. 2.0 (PharmacoEconomic Antibiotic Cost Evaluator). Developed concept, wrote the software – now including Febrile Neutropenia and Combination regimens. Manual published, software distributed by BMS, 1996.
 26. Birmingham MC, Hassett JM, Schentag JJ, Paladino JA. Assessing antibacterial pharmacoeconomics in the intensive care unit. *PharmacoEconomics.* 1997;12:637-647.
 27. Carr JR, Fitzpatrick P, Izzo JL, Cumbo TJ, Birmingham MC, Adelman MH, Paladino JA, Hanson SC, Schentag JJ. Changing the infection control paradigm from off-line to real-time: the experience at Millard Fillmore Health System. *Infect Control Hosp Epidemiol.* 1997;18:255-259.
 28. Schentag JJ, Birmingham MC, Paladino JA, Carr JR, Hyatt JM, Forrest A, Zimmer GS, Adelman MH, Cumbo TJ. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. *Seminars Resp Inf.* 1997;12:278-293.
 29. Bungay K, Osterhaus J, Paladino JA, Sanchez L, editors. Pharmacoeconomics and outcomes: College Version. American College of Clinical Pharmacy, 1997.
 30. Schentag JJ, Hyatt JM, Carr JR, Paladino JA, Birmingham MC, Zimmer GS, Cumbo TJ. Genesis of methicillin-resistant *Staphylococcus aureus* (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant *Enterococcus faecium*, and the importance of antibiotic management and infection control. *Clin Infect Dis.* 1998;26:1204-1214.
 31. Schentag JJ, Birmingham MC, Hyatt JM, Hassett JM, Paladino JA. Methods to control endemic vancomycin resistant enterococci, and strategies for reducing the risk of vancomycin resistant *Enterococcus faecium* outbreaks in surgical ICU patients. *Surg Rounds.* 1998; November (Supplement):12-26.
 32. Paladino JA. Benchmarking antibiotic use in hospitals. (7):22-24. In: Paladino JA, Blondeau JM, eds. Issues in Infection. Choices and consequences: what have we learned about infection in the hospital setting? Cambridge Medical Publications. West Sussex, UK. Wicker House, 1998.
 33. Schentag JJ, Paladino JA. Pharmacodynamic rationale for selecting the fluoroquinolones. *Infect Dis Clin Pract.* 1999;8 (Suppl 1):S23-S27.
 34. Paladino JA, Gudgeon LD, Niederman MS. Pharmacoeconomic method to assess the cost-effectiveness of antibiotic treatment of community-acquired pneumonia. In: Zinner SH, Young LS, Acar JF, Ortiz-Neu C, eds. New Considerations for Macrolides, Azalides, Streptogramins, and Ketolides. Marcel Dekker, Inc., New York 1999;674-679.
 35. Paladino JA. Pharmacoeconomics of antimicrobial therapy. *Am J Health-System Pharm.* 1999;56(Suppl 3):S25-S28.
 36. Paladino JA, Gilliland KK. Antibiotic IV to PO switch therapy for respiratory tract infections: focus on fluoroquinolones. *Antibiot Clin.* 1999;3 (suppl 1):59-64.
 37. Paladino JA. Economic justification of antimicrobial management programs: Implications of antimicrobial resistance. *Am J Health-System Pharm.* 2000;57(suppl 2):S10-12.
 38. Paladino JA, Fong DA, Forrest A, Ramphal R. Cost-effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy for the treatment of febrile episodes in neutropenic patients. *PharmacoEconomics.* 2000;18:369-381.
 39. Paladino JA. Cefepime in the treatment of Nursing Facility-Acquired Pneumonia. *Consultant Pharmacist.* 2000;(Suppl C):16-24.
 40. Dresser LD, Paladino JA. Antimicrobial management of commonly encountered infectious diseases in the long-term care facility. *Consult Pharm.* 2000;15:644-655.
 41. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? *Clin Infect Dis.* 2001;32(suppl 1):S39-46.
 42. Paladino JA. Reducing the economic burden through appropriate antibiotic use. In: Low DE, ed. Appropriate Antibiotic Use. International Congress and Symposium Series 251. The Royal Society of Medicine, London 2001; 37-41.
 43. Paladino JA, Sunderlin JL, Price CS, Schentag JJ. Economic consequences of antimicrobial resistance. *Surg Infect* 2002;In press.
 44. Paladino JA, Callen WA, Quinolones and resistance: are they all alike? *J Antimicrob Chemother.* 2002;In press
 45. Paladino J, Holmes B, Schmidt FJ. Appropriate use of antimicrobials: a practical guide for physicians. Science Press Limited. London. 2002; In press.
 46. Paladino JA. Antimicrobial choices and dosing strategies to maximize efficacy and minimize the development of bacterial resistance. In: Linden PK, Doughty WM, editors. Immunology and Infectious Disease. Kluwer Academic Publishers. Norwell, MA. 2002, In press.
 47. Bhavnani SM, Paladino JA, Callen WA, Forrest A, Gilliland KK, Collins DA, Schentag JJ. An evaluation of fluoroquinolone expenditures and ciprofloxacin susceptibility of *Pseudomonas aeruginosa* among U.S. hospitals.
 48. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of AUC₀₋₂₄/MIC and time above the MIC as predictors of outcome for advanced generation cephalosporins in serious bacterial infections.
 49. Paladino JA, Wynd MA, Schentag JJ. Outcomes of dual individualization of antibiotics. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. Vancouver, WA. Applied Therapeutics, Inc. Fourth Edition; 2003, In revision.